MY160951A - Mesenchymal stem cell differentiation - Google Patents

Mesenchymal stem cell differentiation

Info

Publication number
MY160951A
MY160951A MYPI2011006173A MYPI2011006173A MY160951A MY 160951 A MY160951 A MY 160951A MY PI2011006173 A MYPI2011006173 A MY PI2011006173A MY PI2011006173 A MYPI2011006173 A MY PI2011006173A MY 160951 A MY160951 A MY 160951A
Authority
MY
Malaysia
Prior art keywords
mesenchymal stem
present
stem cell
cell differentiation
provides
Prior art date
Application number
MYPI2011006173A
Other languages
English (en)
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Original Assignee
Scripps Research Inst
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY160951(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Novartis Ag filed Critical Scripps Research Inst
Publication of MY160951A publication Critical patent/MY160951A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2011006173A 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation MY160951A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
MY160951A true MY160951A (en) 2017-03-31

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011006173A MY160951A (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Country Status (30)

Country Link
US (4) US9139633B2 (ref)
EP (1) EP2453921B1 (ref)
JP (1) JP5602850B2 (ref)
KR (3) KR101590834B1 (ref)
CN (2) CN102625830B (ref)
AU (1) AU2010273570B2 (ref)
BR (1) BR112012000914B8 (ref)
CA (1) CA2767826C (ref)
CL (1) CL2012000091A1 (ref)
CO (1) CO6491059A2 (ref)
CR (1) CR20120024A (ref)
CU (1) CU24042B1 (ref)
EA (1) EA023073B1 (ref)
EC (1) ECSP12011604A (ref)
ES (1) ES2541217T3 (ref)
GT (1) GT201200011A (ref)
IL (2) IL217383A (ref)
IN (1) IN2012DN00572A (ref)
MA (1) MA33423B1 (ref)
MX (1) MX2012000707A (ref)
MY (1) MY160951A (ref)
NZ (1) NZ597306A (ref)
PE (2) PE20160507A1 (ref)
PL (1) PL2453921T3 (ref)
PT (1) PT2453921E (ref)
SG (1) SG177318A1 (ref)
TN (1) TN2011000655A1 (ref)
UA (1) UA104031C2 (ref)
WO (1) WO2011008773A2 (ref)
ZA (1) ZA201200078B (ref)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000707A (es) * 2009-07-14 2012-03-21 Scripps Research Inst Diferenciacion de celula madre mesenquimatica.
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN110446037B (zh) 2011-11-08 2022-01-04 韩国电子通信研究院 用于共享候选者列表的方法和装置
HUE035607T2 (en) 2012-06-25 2018-05-28 Brigham & Womens Hospital Inc Targeted therapeutic agents
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
EP2968330B1 (en) 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP4474384A1 (en) 2014-05-13 2024-12-11 Novartis AG Compounds and compositions for inducing chondrogenesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
WO2018087727A1 (en) * 2016-11-14 2018-05-17 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
US12257243B2 (en) 2018-12-06 2025-03-25 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
JP7427665B2 (ja) 2018-12-06 2024-02-05 ノバルティス アーゲー 関節損傷を治療するための軟骨形成を誘導するための６－ヒドロキシ－８－オキサトリシクロ［３．２．１．０２，４］オクタン－２－カルボキサミド誘導体
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO2000053757A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
CA2332109A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1198568B1 (en) * 1999-07-20 2007-07-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
DE60133301T2 (de) * 2000-10-16 2009-05-14 Genentech, Inc., South San Francisco Behandlungsverfahren mit wisp-polypeptiden
US20030120056A1 (en) * 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CN101905024A (zh) * 2001-11-16 2010-12-08 杰南技术公司 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法
ES2897470T3 (es) * 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
WO2004081174A2 (ja) * 2003-03-10 2004-09-23 Japan Science And Technology Agency 間葉系幹細胞検出用マーカー及び該マーカーを用いた間葉系幹細胞の識別方法
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
CN101001643A (zh) * 2004-06-21 2007-07-18 克里夫兰诊所基金会 用于干细胞归巢的ccr配体
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
EP1899457B1 (en) 2005-05-24 2012-09-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
US8609411B2 (en) 2007-05-04 2013-12-17 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
MX2012000707A (es) * 2009-07-14 2012-03-21 Scripps Research Inst Diferenciacion de celula madre mesenquimatica.
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
KR101590834B1 (ko) 2016-02-12
CL2012000091A1 (es) 2012-10-26
UA104031C2 (uk) 2013-12-25
ECSP12011604A (es) 2012-06-29
HK1164169A1 (en) 2012-09-21
US10064918B2 (en) 2018-09-04
US20120177644A1 (en) 2012-07-12
BR112012000914A2 (pt) 2017-08-08
US11241482B2 (en) 2022-02-08
NZ597306A (en) 2014-03-28
EA201200118A1 (ru) 2012-09-28
CU20120007A7 (es) 2013-02-26
PE20120570A1 (es) 2012-05-19
KR20120029472A (ko) 2012-03-26
IL217383A (en) 2016-08-31
EA023073B1 (ru) 2016-04-29
BR112012000914A8 (pt) 2017-12-19
CR20120024A (es) 2012-06-11
BR112012000914B1 (pt) 2021-04-06
IL217383A0 (en) 2012-02-29
US20200108122A1 (en) 2020-04-09
TN2011000655A1 (en) 2013-05-24
IL247310B (en) 2018-04-30
EP2453921A2 (en) 2012-05-23
JP5602850B2 (ja) 2014-10-08
AU2010273570A1 (en) 2012-02-02
KR20160015403A (ko) 2016-02-12
ZA201200078B (en) 2013-01-30
US9139633B2 (en) 2015-09-22
WO2011008773A2 (en) 2011-01-20
SG177318A1 (en) 2012-03-29
PL2453921T3 (pl) 2015-11-30
KR20180000337A (ko) 2018-01-02
CO6491059A2 (es) 2012-07-31
MX2012000707A (es) 2012-03-21
CA2767826A1 (en) 2011-01-20
US20190000922A1 (en) 2019-01-03
US10555990B2 (en) 2020-02-11
GT201200011A (es) 2013-12-10
PT2453921E (pt) 2015-09-25
CU24042B1 (es) 2014-11-27
JP2012533549A (ja) 2012-12-27
US20160213748A1 (en) 2016-07-28
EP2453921A4 (en) 2012-12-19
CN102625830B (zh) 2016-03-02
AU2010273570B2 (en) 2014-07-03
CN105601728B (zh) 2020-01-10
CA2767826C (en) 2015-11-24
CN102625830A (zh) 2012-08-01
PE20160507A1 (es) 2016-05-20
BR112012000914B8 (pt) 2021-05-25
MA33423B1 (fr) 2012-07-03
EP2453921B1 (en) 2015-05-27
CN105601728A (zh) 2016-05-25
IN2012DN00572A (ref) 2015-06-12
ES2541217T3 (es) 2015-07-16
WO2011008773A3 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
MY160951A (en) Mesenchymal stem cell differentiation
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
NZ591626A (en) Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes
WO2011091420A3 (en) Osteogenic cell delivery matrix
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2010003574A (es) Anticuerpos il-23.
MX2011013722A (es) Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
MX2009002816A (es) Proteinas de fusion de albumina.
MX388960B (es) Una población de células madre mesenquimales enriquecida en integrina a10alta y su uso en la prevención y tratamiento de daño o enfermedad ósea y cartílago.
IL250832A0 (en) Beta glycolipids as immunomodulators
WO2009100035A3 (en) Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
WO2009135905A3 (en) Mesenchymal stem cells and bone-forming cells
WO2010033088A8 (en) Method of improving differentiation of chondrogenic progenitor cells
IL173544A0 (en) Use of cxcl6 chemokine in the prevention or repair of cartilage defects
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
UY33219A (es) Cetoenoles cíclicos para terapias
Tawonsawatruk et al. Growth kinetics of rat mesenchymal stem cells from 3 potential sources: bone marrow, periosteum and adipose tissue
GB201213571D0 (en) Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
MX2008011844A (es) Formulaciones de sitaxsentano de sodio.
Jandial et al. Stem cell–mediated regeneration of the intervertebral disc: Cellular and molecular challenges
Pawitan et al. Prospect of umbilical cord mesenchymal stem cell culture waste in regenerative medicine
Rosini et al. Mesenchymal cells are a promising-but still unsatisfying-anti-inflammatory therapeutic strategy for osteoarthritis: a narrative review
IN2012DN05181A (ref)
Wang et al. Rehmannia glutinosa oligosaccharide induces differentiation of bone marrow mesenchymal stem cells into cardiomyocyte-like cells